Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

As part of the University of Oxford’s mission to provide its researchers with the newest state-of-the-art optical imaging equipment and as part of a strategic partnership with the Kennedy Institute of Rheumatology (KIR), the Institute of Developmental and Regenerative Medicine (IDRM), and Carl Zeiss AG (ZEISS), ZEISS has installed a ZEISS Lattice Lightsheet 7 microscope at the KIR.

Lattice lightsheet

The understanding of the numerous and complex processes that underpin human health and disease are dependent on new and advanced imaging techniques that enable the function and behaviour of cells to be observed. Historically, biomedical researchers have made use of a variety of microscopy instruments to try and answer their research questions in different ways. But as many come with limitations in their technical sensitivity, are invasive methods, or are unable to image live cells with spatial context over time, the KIR and IDRM have added a new state-of-the-art microscope to its arsenal of optical imaging technology. 

“The ZEISS Lattice Lightsheet 7 gives us unprecedented resolution to observe biology and its physiological states in four dimensions i.e., three dimensions of space, and over time,” said Professor Marco Fritzsche, Associate Professor and Rosalind Franklin Kennedy Trust Research Fellow. “And it does so in a minimally invasive way. Typically, when you do fluorescence microscopy the cells are damaged or eliminated by the light and that makes it particularly difficult to image in three dimensions. This new innovation from ZEISS overcomes this issue so we can watch biology live as it unfolds over time.”

As the first serial production ZEISS Lattice Lightsheet 7 to be installed globally, it gives the IDRM and KIR the capability to view cells and their cell-to-cell processes in their tissue micro-environment and within whole organism in vivo in space and time. As an example, Professor Michael Dustin, Scientific Director at the KIR, is using the technology to image the formation of an immunological synapse, which will help advance the translation to treatment of human diseases including auto-immune conditions and cancer. Professor Paul Riley, Director of the IDRM, together with Professors Shankar Srinivas and Professor Georg Hollaender will apply the ZEISS Lattice Lightsheet 7 to study the cellular dynamics of embryos during development of their cardiovascular and immune systems, allowing unprecedented insights under physiological conditions.

The strategic partnership between the IDRM and KIR and ZEISS to develop the Lattice Lightsheet 7 technology is unique in Oxford and beyond. “Together we are committed to advancing optical imaging technology and advanced image analysis to improve research in the field of biomedical sciences.” We expect that technologies such as the ZEISS Lattice Lightsheet 7 will replace conventional imaging technologies in the future,” said Marco.

“ZEISS has a long history of close collaboration with cutting edge scientists. This strategic partnership clearly demonstrates that ZEISS still lives the philosophy laid down by its founding partners 175 years ago. This is a very proud moment for everyone involved” said Dr. Ben Ewins, ZEISS account manager for Oxford University.

The strategic collaboration between Oxford and ZEISS at KIR will yield exciting opportunities for innovation in the field imaging.  We [ZEISS] are particularly excited about starting work on some important topics such as software artificial intelligence and large scale data management.  This is a great opportunity for two historic institutions to work together on some extremely relevant and cutting edge topics.

Similar stories

Professor Chris Buckley has joined the Kennedy Institute as Director of Clinical Research

Moving to the University of Oxford with the Arthritis Therapy Acceleration Programme (A-TAP) will help accelerate the discovery of new treatments for inflammatory diseases.

Behind enemy lines: research finds a new ally in the fight against cardiovascular disease hidden within the vessel wall itself

A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters “good” macrophage behaviour within the vessel wall.

More effective treatment found for patients hospitalised with COVID-19 pneumonia

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

NDORMS researchers honoured in the Recognition Of Distinction Scheme 2021

Sally Hopewell and John Christianson have been awarded the title of ‘Full Professor’ in the University of Oxford’s Recognition Of Distinction Scheme 2021.

New Oxford-Zeiss Centre of Excellence opens at the University of Oxford

The Kennedy Institute for Rheumatology and the Institute of Developmental and Regenerative Medicine announce the launch of the Oxford-Zeiss Centre of Excellence, providing state-of-the-art imaging technologies to lead future discoveries in global health and disease.

HOPE-c opens up for recruitment

Researchers in the Centre for OA Pathogenesis Versus Arthritis at the Kennedy Institute of Rheumatology and Imperial College London are looking to recruit adults with painful hand osteoarthritis for an observational study to help uncover why people living with the condition experience different patterns of pain.